FREQUASENSE LIMITED
Company number 12614398 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
-£265,934
Balance sheet as at 2025-05-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2020-05-20
- Registered office
- Suite 5, Second Floor Bulman House, Regent Centre, Newcastle Upon Tyne, NE3 3LS
- Postcode
- NE3 3LS
- Capital
- 210 GBP
- Accounts category
- Unaudited Abridged
- Charges
- 0 outstanding
Accounts
- Last made up to
- 2025-05-31
- Next due by
- 2027-02-28
- Financial year end
- 31 May
Confirmation statement
- Last statement dated
- 2025-05-20
- Next due by
- 2026-06-03
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 0 current · 9 resigned
Contact details
- Website
- frequasense.co.uk
Frequasense has developed SepsisPlus, a unique cost-effective point of care platform for the rapid detection of sepsis. The company is led by a strong team with decades of Industry experience, clinical expertise in infectious disease and Sepsis as well as in depth biochemical and medical device engineering expertise. OUR why Our Mission Our Mission is
The class of 2020
41%
of the 595 companies in this sector incorporated in 2020 are still active today; 55% have since been dissolved.
A fact about the year, not a forecast for this company.